Form 4: Director Valerie Odegard Receives Odyssey Therapeutics Grant

Director Valerie Odegard was granted 27,393 stock options in Odyssey Therapeutics, Inc. with an exercise price of $18.00.

Summary

• Valerie Odegard, a Director at Odyssey Therapeutics, Inc., was granted 27,393 stock options.
• The options have an exercise price of $18.00 per share.
• The grant date for these derivative securities was May 7, 2026.
• The options are scheduled to vest in full on May 7, 2027, contingent upon continued service.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• Potential future dilution of existing shareholders upon the exercise of these options.

Risks

• Vesting is subject to the continued service of the director, creating a dependency on personnel retention.

Future Outlook

The options vest in full on May 7, 2027, provided the director remains in service to the company.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard practice in the biotechnology sector to incentivize long-term strategic oversight and align board interests with corporate performance.

Comparison to Industry Standards

• The use of time-based vesting (one year) is consistent with standard corporate governance practices for non-employee directors in the life sciences industry.

Stakeholder Impact

• Shareholders may experience minor dilution if these options are exercised in the future.

Next Steps

• Vesting of options on May 7, 2027.

Key Dates

Keywords

Odyssey Therapeutics, ODTX, Form 4, Insider Trading, Stock Options, Director Compensation